MarketAnalysisMarketAnalysis
NYSE:RMD

ResMed Inc. - NYSE:RMD - Comprehensive analysis

Free evaluation through quantitative algorithms ResMed Inc. - NYSE:RMD

Quant Rating

1

Strong Sell

2

Sell

3

Hold

4

Buy

5

Strong Buy


The overall quant rating is not an average of the factor grades listed.Instead, it gives greater weight to the metrics with the strongest predictive value.

Growth-Scoring Model Detail

Name

Fatcor
Percentage

Total Revenue Growth Over Prior Year

9.38

Market

72

Sector

63

Gross Profit Growth Over Prior Year

15.58

Market

83

Sector

70

EBITDA Growth Over Prior Year

25.1

Market

84

Sector

77

EBITA Growth Over Prior Year

26.8

Market

86

Sector

74

EBIT Growth Over Prior Year

28.4

Market

85

Sector

74

Earnings from Cont. Ops. Growth Over Prior Year

40.2

Market

82

Sector

73

Net Income Growth Over Prior Year

40.2

Market

81

Sector

71

Normalized Net Income Growth Over Prior Year

33.7

Market

84

Sector

69

Diluted EPS before Extra Growth Over Prior Year

40.2

Market

80

Sector

70

A/R Growth Over Prior Year

12.51

Market

80

Sector

74

Inventory Growth Over Prior Year

-12.7

Market

8

Sector

13

PPE Net Growth Over Prior Year

-4.83

Market

16

Sector

48

Total Assets Growth Over Prior Year

3.42

Market

54

Sector

58

Tangible Book Value Growth Over Prior Year

85

Market

93

Sector

87

Common Equity Growth Over Prior Year

17.21

Market

82

Sector

74

Cash from Ops. Growth Over Prior Year

36.8

Market

90

Sector

73

CAPEX Growth Over Prior Year

-27.52

Market

9

Sector

34

Dividend per Share Growth Over Prior Year

9.78

Market

80

Sector

98

Levered Free Cash Flow Growth Over Prior Year

35.9

Market

80

Sector

68

Unlevered Free Cash Flow Growth Over Prior Year

31.1

Market

78

Sector

67

Profitability-Scoring Model Detail

Name

Fatcor
Percentage

Gross Margin %

60

Market

73

Sector

58

SG&A Margin %

19.34

Market

63

Sector

33

EBITDA Margin %

34.8

Market

71

Sector

95

EBITA Margin %

32.7

Market

85

Sector

96

EBIT Margin %

31.7

Market

86

Sector

97

Earnings from Cont. Ops Margin %

25.3

Market

85

Sector

96

Net Income Margin %

25.3

Market

85

Sector

96

Net Income Avail. for Common Margin %

25.3

Market

86

Sector

96

Normalized Net Income Margin %

19.52

Market

87

Sector

96

Levered Free Cash Flow Margin %

22.4

Market

81

Sector

93

Unlevered Free Cash Flow Margin %

22.7

Market

77

Sector

92

Return on Assets %

13.89

Market

91

Sector

97

Return on Capital %

16.3

Market

85

Sector

96

Return on Equity %

25.7

Market

70

Sector

94

Return on Common Equity %

25.7

Market

70

Sector

95

Total Asset Turnover

0.7

Market

68

Sector

78

Sub-Scoring Model

Valuation
Momentum
Growth
Profitability
80
60
40
20
Valuation: 33
Momentum: 84
Growth: 70
Profitability: 79

Valuation-Scoring Model Detail

Name

Fatcor
Percentage

TEV/LTM Total Revenue

8.01

Market

82

Sector

73

TEV/LTM EBITDA

21.4

Market

83

Sector

73

P/LTM Normalized EPS

39.7

Market

70

Sector

67

P/BV

6.98

Market

74

Sector

83

TEV/LTM Unlevered FCF

34.1

Market

66

Sector

72

Momentum-Scoring Model Detail

Name

Fatcor
Percentage

1M Price Performance

11.76

Market

95

Sector

81

3M Price Performance

16.03

Market

79

Sector

64

6M Price Performance

20.5

Market

88

Sector

81

9M Price Performance

16.46

Market

76

Sector

80

1Y Price Performance

35.7

Market

81

Sector

81

Start analyzing ResMed Inc. - NYSE:RMD with easy-to-understand research reports

Start analyzing Recent popular companies with easy-to-understand research reports